Cationic Amphiphiles of Methylphosphonates and Cholesterol Phosphocholines and Their Homo Derivatives

D. A. Predvoditelev, M. A. Malenkovskaya, and E. E. Nifant'ev

Moscow State Pedagogical University, Moscow, Russia

Received April 24, 2002

Abstract—A method of synthesis of $(P \rightarrow O)$ and $(P \rightarrow N)$ -choline cholesteryl methylphosphonates and their homo derivatives of the cationic type is developed. These compounds were obtained by the Arbuzov reaction between bromomethane and cyclic cholesteryl phosphorous esters and amidoesters and subsequent aminolysis of the intermediate bromoalkyl phosphonates. Alkylation of trimethylamine with cholesteryl ethanediyl and propanediyl phosphates gives cholesterol phosphocholines and their homo derivatives.

In the last ten years there has been considerable synthetic work on cholesterol-containing phospohorusfree cationic amphiphiles [1, 2]. Such lipids are being actively studied as components of cationic liposoms for transport of genetic material into the cell, as well as medicinals [3, 4]. At the same time, we have been the only who synthesized phosphorus lipids with cholesterol as structural domain. Hence, the synthesis of cholesterol-containing thiophospholipids, such as phosphomethylcolamines, phosphocholines, and phosphodiols [5], as well as of amidodiester $(P \rightarrow N)$ cholesterol phospholipids of the cationic type [6] has been accompished. Cholesteryl phospholipids of the cationic type, owing to specific properties of cholesterol, may present considerable interest in terms of transfection effectiveness [7].

Proceeding with our research, we set ourselves the task to develop synthetic approaches to formerly unknown cationic methylphosphonate analogs of cholesterol, as well as to cholesterol phosphocholines and their homo derivatives.

The first line of out work was based on the use of alkanediyl cholesteryl phosphites in the synthesis of cationic cholesteryl methylphosphonates. To this end, we performed Arbuzov alkylation of the available ethanediyl and propanediyl phosphites (**I**, **II**) with bromomethane.

The reaction was carried out at 110–120°C. The yield of bromoalkyl phosphonates **III**, **IV** reached 40–65%. The products are colorless oils. Importantly, these compounds are stable and can be handled in dark closed vessels at 5°C for several months. Reaction progress was controlled by ³¹P NMR spectroscopy. The ³¹P–{¹H} NMR spectra of cholesteryl methylphosphonates **III**, **IV** contain singlets at $\delta_{\rm P}$



30.34 and 30.02 ppm, respectively. The ¹H NMR spectra of these compounds show expected signals of all proton groups.¹ Hence, the PCH₃ protons, due to coupling with phosphorus, appear as a doublet at δ 1.47 ppm (²J_{PH} 17.04–17.50 Hz). The CH₂Br methylene protons give characteristic triplet signals at δ 3.48–3.49 ppm, the cholesteryl C³HOP proton, a multiplet at δ 4.38 ppm, and the cholesteryl C⁶H= proton, due to coupling with the C⁷H₂ methylene protons, a doublet at δ 5.38 ppm. The rest signals in the spectra of the acyclic cholesteryl phosphonates were roughly the same as in the spectra of the starting phosphites **I**, **II** (see Experimental).

¹ Analysis of the ¹H NMR spectra was carried out with account for data of Facke and Berger [8] who performed detailed assignment of the ¹H NMR spectra of cholesterol.

Bromoalkyl phosphonates **III**, **IV** were used for preparing cationic amphiphiles **V**, **VI**. To this end, phosphonates **III**, **IV** were reacted with *i*th trimethylamine.



Quarternization of trimethylamine occurred at room temperature (about 22°C) within 12 h. Earlier quarternization of glycerol bromoalkyl phosphonates in the synthesis of cationic amphiphiles of phosphoglycerols was also performed at room temperature, but for a longer time (70–72 h) [9]. Reaction progress was controlled by TLC. The yields of chromatographically pure ammonium compounds **V**, **VI** were 52–65%. They are solid amorphous substances.

The ¹H NMR spectra of phosphonates **V**, **VI** contain singlets of the N⁺(CH₃)₃ group at δ 3.32–3.40 ppm. The triplets of the CH₂Br methylene protons have disappeared, and, instead of them, multiplet signals of the CH₂N⁺(CH₃)₃ methylene protons have appeared. The other signals in the spectra of compounds **V**, **VI** practically coincide with those of the starting bromoalkanols (see Experimental).

Cholesteryl alkanediyl phosphates were also used for preparing cholesterol phosphocholine and its homo derivative. As the starting material for preparing cholesterol phosphocholine we used cholesteryl ethanediyl phosphite (I) which was oxidized to cholesteryl ethanediyl phosphate (VII) with urea hydrogen peroxide adduct (20° C, 5 h). The product was isolated by column chromatograpghy in 40% yield.



To extend the scope of the method of synthesis of cholesterol phosphocholines, we made an attempt to oxidize cholesteryl propanediyl phosphite (II). Unfortunately, this oxidation failed. Therefore, the target product was prepared by reacting cholesterol (VIII) with propanediyl phosphorochloridate in the presence of triethylamine.



RUSSIAN JOURNAL OF GENERAL CHEMISTRY Vol. 73

Propanediyl phosphorochloridate proved to be much less reactive compared to propanediyl phosphorochloridite toward cholesterol (**VIII**) and could only be reacted at 80° C within 8 h. The yield of the target product **IX** isolated on a silica gel column was as low as 35%.

Cholesteryl alkanediyl phosphates **VII, IX**, unlike the corresponding thiophosphates [5], are unstable hygroscopic crystalline substances. They can be stored without decomposition in closed vials only for several days at -5° C.

The purity and structure of phosphates VII, IX was proved by TLC and ³¹P and ¹H NMR spectroscopy. The ³¹P NMR spectra of compounds VII, IX contained singlets at δ_p 15.98 and -8.76 ppm, respectively. The ¹H NMR spectra of phosphates VII, IX showed signals characteristic of all proton groups. Thus, the spectrum of ethanediyl phosphate VII contained a multiplet of methylene protons of the phospholane ring at δ 4.40 ppm, whereas the spectrum of propanediyl phosphate IX, characteristic multiplets of protons of the phosphorinane ring at δ 2.20 and 4.46 ppm. The other signals in the spectra of phosphates VII, IX were consistent with the proposed structures (see Experimental).

To pass to cholesterol phosphatide structures of the betain type, we performed alkylation of trimethylamine with phosphates **VII**, **IX**.

VII, IX
$$\xrightarrow{\mathrm{N(CH_3)_3}}$$
 R-O-P-O(CH₂)_n $\overset{+}{\mathrm{N(CH_3)_3}}$,
O⁻⁻O
X, XI

$$n = 2$$
 (III, V), 3 (IV, VI).

The reactions with trimethylamine were carried out in benzene at 90-100°C for 30-35 h. Then benzene was removed in a vacuum, and the remaining target products were washed with hexane. Cholesterol phosphocholine X and phosphohomocholine XI were obtained as colorless crystals in 30 and 42% yields, respectively. Note that in the case of cholesterol thiophosphocholines prepared by the analogous procedure from cholesteryl thiophosphates the yields of the target products were higher, 40 and 80%, respectively [5]. The 31 P NMR spectra of phosphocholines X, XI contained singlet signals at $\delta_{\rm P}$ –0.82 and 0.27 ppm, respectively. The ¹H NMR spectra of these compounds displayed singlets of ammonium methyl protons at δ 3.32–3.40 ppm. In addition, the spectrum of betain **X** contained multiplets of β -methylene protons of the $CH_2N^+(CH_3)_3$ group at δ 3.65 ppm, that of betaine XI, multiplets of β - and γ -methylene protons of the $CH_2CH_2N^+(CH_3)_3$ group at δ 2.38 ppm No. 10 2003

and 2.85 ppm. The other signals in the ¹H NMR spectra had only slightly different chemical shifts compared to the respective signals of the starting cyclic phosphates **VII**, **IX** (see Experimental).

In the final stage of this work we applied the proposed synthetic scheme for preparing cholesteryl ethylamidophosphonate of the cationic type. Such $(P \rightarrow N)$ phospholipids, unlike $(P \rightarrow O)$ phospholipids, have a more polar phosphoryl group due to the presence of a phosphamide fragment in its structure, and this may influence the properties of membrane constructions on their basis.



The synthesis of lipid aminophosphonate amphiphiles was begun from alkylation of the previously prepared by us [5] cholesteryl phosphoramidite **XII** with bromomethane (90°C, 8 h). Then cholesteryl phosphonamidate **XIII** was purified by column chromatography on silica gel and reacted with trimethylamine to obtain cationic ammonium phospholipid **XIV** (22°C, 12 h). This compound was precipitated from benzene as a white powder. The yield of chromatographically pure product **XIV** was 42%.

The ³¹P NMR spectra of compounds XIII, XIV contained two singlet signals at δ_p 33.12 and 33.42 (XIII) and 34.39 and 34.69 ppm (XIV). Such a complification of the spectra is connected with the fact that these compounds are present as diastereomeric pairs due to the cholesteryl radicals and racemic phosphorus atom. The ¹H NMR spectra of phosphonates XIII, XIV contained signals characteristic of all proton groups, sometimes complicated by stereomeric anisochronicity. Hence, the PCH₃ protons appear as doublets at δ 1.45 ppm, and the NCH₃ protons, as a doublet at δ 2.75–3.40 ppm. In addition, the ¹H NMR spectrum of compound XIII showed a triplet at δ 3.02 ppm, characteristic of CH₂Br groups. The spectrum of choline phosphonate XIV differed from the spectrum of the acyclic compound **XIII** by the presence of a singlet at δ 3.50 ppm from the $N^+(CH_3)_3$ methyl protons, a multiplet of the CH_2N^+ . $(CH_3)_3$ methylene protons at δ 3.56 ppm, as well as by the absence of the CH₃Br triplet. All the other proton signals of compounds **XIII**, **XIV** almost did not differ from each other (see Experimental).

The present work resulted in the synthesis of a group of original phosphocholesterol systems belonging to cationic phospholipids. The synthesized compounds offer interest as objects for research into lipid exchange. Moreover, they can be used for studying the behavior of a polar head incorporated into the rigid lipid matrix.

EXPERIMENTAL

The ¹H NMR spectra were obtained on a Bruker WM-250 (250 MHz) spectrometer against internal HMDS. Signal assignment was made on the basis of double-resonance data. The ${}^{31}P-{}^{1}H$ spectra were measured on a Bruker WP-80 SY spectrometer (32.4 MHz) against external 85% phosphoric acid. Column chromatography was performed on a column 15 mm in diameter, filled on Silica gel L (100-160 µm). Thin-layer chromatography was performed on Silufol UV-254 plates, eluents 3:1 benzene-dioxane (A), 3:1 hexane-dioxane (B), and 65:25:4 chloroform-methanol-water (C). The melting points were measured in a sealed capillary at a heating rate of 1 deg/min. The urea hydrogen peroxide adduct was prepared according to [10], 2-chloro1,3,2-dioxaphospholane, according to [11], 2-chloro-1,3,2-dioxaphosphorinane, according to [12], and propanediyl prosphorochloridite, according to [13].

2-Bromoethyl cholesteryl methylphosphonate (III). A sealed ampule with a solution of ethanediyl phosphite (I) (prepared according to [5] from 2 g of cholesterol, 0.64 g of ethanediyl phosphorochloridite, and 0.5 g of triethylamine) and 2.95 g of bromomethane in 20 ml of anhydrous benzene was kept for 12 h at 110°C. The solvent was removed in a vacuum, and ethanediyl phosphonate III was isolated on a column of silica gel (20 g), filled with hexane. Compound III was eluted with 50 ml of a 5:1 hexane-dioxane mixture. The solvents were removed in a vacuum, and the residue was kept for 2 h at 40°C (1 mm). Yield 1.2 g (40%), n_D^{20} 1.5057, R_f 0.55 (A), 0.27 (B). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.68– 2.47 (cholesterol H),² 1.47 d (3H, PCH₃, ${}^{2}J_{HP}$ 17.50 Hz), 3.48 t (2H, CH₂Br), 4.24 m (3H, POCH₂, cholesterol OPC³H), 5.33 d (1H, cholesterol C⁶H=, ${}^{3}J_{HH}$ 3.40 Hz). 31 P NMR spectrum (chloroform), δ_p, ppm, δ_p: 30.34 s. Found,%: C 63.10; H 9.25; P 5.50. C₃₀H₅₂BrO₃P. Calculated,%: C 63.03, H 9.17, P 5.42.

² Here and hereafter, the region at δ 0.68–2.47 ppm, characteristic of protons on the C^{1,2}, C^{4,5}, and C^{7–27} atoms of the phosphocholesterol moiety [8], is labeled (cholesterol H).

3-Bromopropyl cholesteryl methylphosphonate (**IV**). A sealed ampule with a solution of propanediyl phosphite (**II**) (prepared according to [5] from 2.5 g of cholesterol, 0.73 g of propanediyl phosphorochloridite, and 0.62 g of triethylamine), and 3 g of bromomethane in 20 ml of anhydrous benzene was kept at 120°C for 15 h. The solvent was removed in a vacuum, and phosphonate **IV** was isolated on a column of silica gel (30 g), filled with hexane. Compound **IV** was eluted with 50 ml of a 3:1 hexane– dioxane mixture. The solvents were removed in a vacuum, and the residue was kept for 2 h at 40°C (1 mm). Yield 2.5 g (65%), n_D^{20} 1.4981. R_f 0.60 (A), 0.30 (B). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.67– 2.47 (cholesterol H), 1.47 d (3H, PCH₃, ²J_{PH} 17.04 Hz), 2.61 m (2H, POCH₂–CH₂–CH₂, ³J_{HH} 7.15 Hz), 3.49 t (2H, CH₂Br, ³J_{HH} 6.6 Hz), 4.14 m (2H, POCH₂), 4.38 m (chlesterol OPC³H), 5.38 d (1H, cholesterol C⁶H=, ³J_{HH} 3.80 Hz). ³¹P NMR specrum (chloroform), δ_p , ppm: 30.02 s. Found,%: C 63.61; H 9.51; P 5.43. C₃₁H₅₄BrO₃P. Calculated,%: C 63.57; H 9.29, P 5.29.

Cholesteryl 2-(dimethylamino)ethyl methylphosphonate bromomethylate (V). A sealed ampule with a solution of 1 g of phosphonate **III** and 0.36 g of trimethylamine in 10 ml of anhydrous benzene was kept at room temperature for 12 h. To remove the solvent, the gel-like reaction mixture was kept for 0.5 h at 40°C (1 mm). Yield 0.6 g (55%), mp 210-212°C (begins to melt at 185°C), R_f 0.60 (C). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.67-2.38 (cholesterol H), 1.56 d (3H, PCH₃, ${}^{2}J_{PH}$ 17.05 Hz), 3.54 s (9H, N^+Me_3), 4.22 br.m (2H, POCH₂CH₂N⁺), 4.44 br.m (2H, POC H_2 C H_2 N⁺), 4.54 br.m (1H, cholesterol OPC³H), 5.39 br.m (1H, cholesterol C⁶H=). ³¹P NMR spectrum (chloroform), δ_P , ppm: 31.00 s. Found, %: C 63.01; H 9.98; P 5.01. C₃₃H₆₁. BrNO₃P. Calculated, %: C 62.84; H 9.75; P 4.91.

Cholesteryl 3-(dimethylamino)propyl methylphosphonate bromomethylate (VI) was obtained analogously to phosphonate V from 1.5 g of compound IV and 0.62 g of trimethylamine in 15 ml of anhydrous benzene. Yield 1.02 g (62%), mp 255– 257°C (begins to melt at 210°C), R_f 0.63 (C). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.63–2.40 (cholesterol H), 1.49 d (3H, PCH₃, ³J_{PH} 17.18 Hz), 2.23 br.s (2H, POCH₂–CH₂–CH₂N⁺), 4.17 br.m (1H, cholesterol OPC³H), 5.35 br.m (1H, cholesterol C⁶H=). ³¹P NMR spectrum (chloroform), δ_P , ppm: 30.69 s. Found, %: C 63.51; H 10.01; P 5.05. C₃₄H₆₃BrNO₃P. Calculated, %: C 63.33; H 9.85; P 4.80.

2-Cholesteryloxy-1,3, $2\lambda^5$ -dioxaphospholane 2-oxide (VII). To a solution of ester I (prepared according to [5] from 1 g of cholesterol and 0.32 g of ethanediyl phosphorochloridite in the presence of 0.3 g of triethylamine) in 20 ml of anhydrous benzene, 0.2 g of urea hydrogen peroxide adduct was added at room temperature, and the reaction mixture left to stand at that temperature for 5 h. Excess adduct was filtered off, and the solvent was removed in a vacuum. Compound **VII** was purified on a column of silica gel (10 g), filled with hexane, eluent 5:1 hexane-dioxane (40 ml). The solvents were removed in a vacuum, and the residue was kept for 2 h at 40°C (1 mm). Yield 0.38 g (40%), mp 145–148°C, R_f 0.70 (A), 0.45 (B). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.68-2.47 (cholesterol H), 4.40 m (4H, OCH₂CH₂O), 4.47 m (1H, cholesterol OPC³H), 5.39 d (1H, cholesterol C⁶H=, ${}^{3}J_{\text{HH}}$ 4.30 Hz). ${}^{31}\text{P}$ NMR spectrum (chloroform), δ_{P} , ppm: 15.98 s. Found, %: C 36.91, H 9.89, P 6.03. C₂₉H₄₉O₄P. Calculated, %: C 36.56, H 10.02, P 6.29.

2-Cholesteryloxy-1,3, $2\lambda^5$ -dioxaphosphorinane **2-oxide** (IX). To a solition of a mixture of 1 g of cholesterol (VIII) and 0.25 g of triethylamine in 30 ml of anhydrous benzene, a solution of 0.4 g of propanediyl phosphorochloridate in 5 ml of the same solvent was added dropwise with stirring at 0°C. The temperature of the reaction mixture was gradually raised to 80°C and maintained for 8 h. Then triethylamine hydrochloride was filtered off, and benzene was removed in a vacuum. Compound IX was purified on a column of silica gel (15 g), filled with hexane, eluent 3:1 hexane-dioxane (50 ml). The solvent was removed in a vacuum, and the residue was kept for 2 h at 40°C (1 mm). Yield 0.45 g (35%), mp 190-192°C, R_f 0.70 (A), 0.50 (B). ¹H NMR spectrum (CDCl₃), δ, ppm: 0.67-2.46 (cholesterol H), 2.20 m (2H, OCH₂–CH₂–CH₂O), 4.46 m (5H, POCH₂CH₂· CH_2O , cholesterol OPC^3H), 5.41 d (1H, cholesterol $C^{6}H=$, ${}^{3}J_{HH}$ 4.85 Hz). ${}^{31}P$ NMR spectrum (chloroform), δ_{P} , ppm: -8.76 s. Found,%: C 71.38,H 10.31, P 6.23. C₃₀H₅₁O₄P. Calculated,%: C 71.11; H 10.14; P 6.11.

Cholesterol phosphocholine X. A sealed ampule with a solution of 0.4 g of phosphate **VII** and 0.15 g of trimethylamine in 5 ml of anhydrous benzene was heated at 90–95°C for 30 h. The solvent was removed in a vacuum, and the oily residue was washed with hexane (2×5 ml) and dried for 2 h at 40°C (1 mm). Yield 0.3 g (30%), mp 285–286°C (begins to melt at 250°C), R_f 0.00 (A), 0.30 (C). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.67–2.42 (cholesterol H), 3.40 s (9H, N⁺Me₃), 3.65 br.s (2H, POCH₂CH₂N⁺), 4.38 br.m (1H, cholesterol OPC³H), 5.40 br.m (1H, cholesterol C⁶H=). ³¹P NMR spectrum (chloroform), δ_P , ppm: -0.2 s. Found, %: C 69.72; H 10.49, P 5.43.

RUSSIAN JOURNAL OF GENERAL CHEMISTRY Vol. 73 No. 10 2003

 $C_{32}H_{58}NO_4P$. Calculated, %: C 69.65; H 10.60, P 5.61.

Cholesterol phosphohomocholine (XI) was prepared analogously from 0.5 g of phosphate **IX** and 0.25 g of trimethylamine in 10 ml of anhydrous benzene at 90–100°C for 35 h. Yield 0.3 g (42%), mp 300–301°C (decomp.) (begins to melt at 285°C), R_f 0.00 (A), 0.25 (B). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.67–2.48 (cholesterol H), 2.38 br.m (2H, POCH₂CH₂CH₂N⁺), 2.85 br.m (2H, POCH₂CH₂C CH_2 N⁺), 3.32 s (9H, N⁺Me₃), 3.75 br.m (2H, POCH₂C CH_2 CH₂N⁺) 4.20 br.m (1H, cholesterol OPC³H), 5.35 br.m (1H, cholesterol C⁶H=). ³¹P NMR spectrum (chloroform), δ_p , ppm: 0.27 s. Found, %: C 70.15; H 10.81, P 5.58. C₃₃H₆₀NO₄P. Calculated, %: C 70.04; H 10.69; P 5.47.

Cholesteryl N-(2-bromoethyl)-N,P-dimethyl**phosphonamidate** (XIII). A sealed ampule with a solution of 2-cholesteryloxy-3-methyl-1,3,2-oxazaphospholane (XIII) (prepared according to [5] from 2 g of cholesterol and 2.56 g of hexaethylphosphorous triamide and subsequent reaction of the intermediate cholesterol tetraethylphosophorodiamidite with 0.4 g of N-methylethanolamine) and 3.5 g of bromomethane in 25 ml of anhydrous benzene was kept at 90°C for 8 h. The solvent was removed in a vacuum, and phosphonate XIII was isolated on a column of silica gel (15 g), filled with hexane, eluent 1:1 hexane-dioxane (50 ml). The solvent was removed in a vacuum, and the residue was kept for 2 h at 40°C (1 mm). Yield 1.4 g (45%), n_D^{20} 1.4785, R_f 0.45 (A), 0.19 (B). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.65–2.47 (cholesterol H), 1.45 d (3H, PCH₃, ${}^{2}J_{PH}$ 12.02 Hz), 2.06 m and 2.66 m (2H, PNCH₂CH₂, ${}^{3}J_{PH}$ 9.35 Hz), 2.99 t and 3.02 t (2H, CH₂Br, ${}^{3}J_{HH}$ 7.14 Hz), 3.43 d (3H, PNCH₃, ${}^{3}J_{HP}$ 2.20 Hz), 4.30 m (1H, cholesterol OPC³H), 5.36 d (1H, cholesterol C⁶H=, ${}^{3}J_{HH}$ 5.50 Hz). 31 P (chloroform), δ_{P} , ppm: 33.12 s and 33.42 s, intensity ratio 10:8. Found, %: C 63.72; H 9.63. C₃₁H₅₅BrNO₂P. Calculated, %: C 63.68, H 9.48, P 5.30.

Cholesteryl *N*-(2-bromoethyl)-*N*,*P*-dimethylphosphonamidate bromomethylate (XIV) was obtained similarly to phosphonate V from 1 g of compound XIII and 0.45 g of triethylamine in 10 ml of anhydrous benzene. Yield 0.46 g (42°C), mp 225– 227°C (begins to melt at 205°C), R_f 0.69 (C). ¹H NMR spectrum (CDCl₃), δ , ppm: 0.66–2.37 (cholesterol H), 1.46 d (3H, PCH₃, ²J_{PH} 15.79 Hz), 1.46 d (3H, PCH₃, ${}^{2}J_{PH}$ 15.79 Hz), 2.75 d (3H, PNCH₃, ${}^{3}J_{PH}$ 9.81 Hz), 3.50 s (9H, N⁺Me₃), 3.56 br.m (2H, PNCH₂. CH₂), 4.03 br.m (3H, PNCH₂CH₂ and cholesterol OPC³H), 5.36 br.m (1H, cholesterol C⁶H=). 31 P NMR spectrum (chloroform), δ_{P} , ppm: 34.39 and 34.69, intensity ratio 10:8. Found, %: C 63.53; H 10.21, P 4.95. C₃₄H₆₄BrN₂O₂P. Calculated, %: C 63.43; H 10.02, P 4.81.

ACKNOWLEDGMENTS

The work was financially supported by the Russian Foundation for Basic Research (project no. 01-03-32459).

REFERENCES

- 1. Okayama, R., *FEBS Lett.*, 1997, vol. 408, no. 2, pp. 232–234.
- Konstantinova, T.V., Klykov, V.N., and Serebrennikova, G.A., *Bioorg. Khim.*, 2001, vol. 27, no. 6, pp. 453–456.
- Miller, A.D., Angew. Chem. Int. Ed. Engl., 1998, vol. 37, nos. 13–14, pp. 1768–1785.
- Maslov, M.A., Sycheva, E.V., Morozova, H.G., and Serebrennikova, G.A., *Izv. Ross. Akad. Nauk*, 2000, vol. 3, p. 385–399.
- Predvoditelev, D.A., Malenkovskaya, M.A., and Nifant'ev, E.E., *Trudy 13 mezhdunarodnoi konferentsii po khimii soedinenii fosfora (ICCPC-XII)* (Proc. 13-th Conf. on Chemistry of Organophosphorus Compounds), St. Petersburg, 2002, p. 130.
- Predvoditelev, D.A., Kosarev, G.V., Suvorkin, S.V., and Nifant'ev, E.E., *Zh. Org. Khim.*, 2002, vol. 38, no. 121, p. 1671.
- Tarakhovskii, Yu.S. and Ivanitskii, T.V., *Biokhimiya*, 1998, vol. 63, no. 6, p. 723–725.
- Facke, T. and Berger, S., *Tetrahedron*, 1995, vol. 51, no. 12, pp. 3521–3524.
- Alarkon, Kh. Kh., Predvoditelev, D.A., and Nifant'ev, E.E., *Bioorg. Khim.*, 1978, vol. 4, no. 11, pp. 1513–1519.
- Nifant'ev, E.E., Rasadkina, E.N., and Yankovich, I.V., *Zh. Obshch. Khim.*, 1999, vol. 69, no. 1, pp. 36–42.
- 11. Gefter, E.L., Zh. Obshch. Khim., 1956, vol. 26, no. 5, pp. 1440–1443.
- 12. Zwierzak A., *Can. J. Chem.*, 1967, vol. 45, no. 21, pp. 2501–2512.
- 13. US Patent 2892862, Chem. Abstr., 1960, vol. 54, 15740.